GCM
PBYI icon

Gladius Capital Management’s Puma Biotechnology PBYI Stock Holding History

Gladius Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-9,811
Closed -$28K – 472
2022
Q2 		$28K Buy
+9,811
New +$24.4K ﹤0.01% 301

Other funds holding PBYI

CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $783M AUM 81.58% 1-Year Est. Return

Gladius Capital Management's PBYI Position: Q3 2022 in Review

Gladius Capital Management sold out of Puma Biotechnology (PBYI) in Q3 2022, closing a stake of 9,811 shares — an estimated $28K sold.

Gladius Capital Management first reported a position in PBYI in Q2 2022 and held it in 1 quarter. The position peaked at $28K in Q2 2022. 83 funds tracked by Wall St. Rank hold PBYI as of Q3 2022.

  • Gladius Capital Management reported no remaining Puma Biotechnology position as of Q3 2022 after selling out during the quarter.
  • Gladius Capital Management sold 9,811 Puma Biotechnology shares in Q3 2022, an estimated $28K.
  • Gladius Capital Management first reported a position in Puma Biotechnology in Q2 2022 and held it in 1 quarter.
  • Gladius Capital Management's Puma Biotechnology position peaked at $28K in Q2 2022.
  • 83 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2022.

Based on Gladius Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.